Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MALIBU trial – ibrutinib + rituximab in untreated marginal zone lymphoma
2018-002364-44Phase 2Active
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and rituximab in extranodal marginal zone B-cell lymphoma (EMZL), splenic marginal zone lymphoma (SMZL) and nodal marginal zone B-cell lymphoma (NMZL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoint: Complete response rate at 12 months. Started Dec 2019; status: active.
02
Drugs
ibrutinibrituximab
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)splenic marginal zone lymphoma (SMZL)nodal marginal zone B-cell lymphoma (NMZL)
Beyond the preview
Go deeper on 2018-002364-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002364-44.